NYSE:EBS Emergent BioSolutions (EBS) Stock Price, News & Analysis $4.68 -0.25 (-4.98%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$4.86 +0.19 (+4.04%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Emergent BioSolutions Stock (NYSE:EBS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Emergent BioSolutions alerts:Sign Up Key Stats Today's Range$4.53▼$4.9450-Day Range$4.68▼$11.6152-Week Range$1.82▼$15.10Volume1.31 million shsAverage Volume2.64 million shsMarket Capitalization$254.03 millionP/E RatioN/ADividend YieldN/APrice Target$14.33Consensus RatingBuy Company OverviewEmergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Read More… Remove Ads Emergent BioSolutions Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreEBS MarketRank™: Emergent BioSolutions scored higher than 85% of companies evaluated by MarketBeat, and ranked 166th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEmergent BioSolutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEmergent BioSolutions has only been the subject of 1 research reports in the past 90 days.Read more about Emergent BioSolutions' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Emergent BioSolutions are expected to grow in the coming year, from ($0.63) to $2.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent BioSolutions is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent BioSolutions is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEmergent BioSolutions has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Emergent BioSolutions' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.51% of the float of Emergent BioSolutions has been sold short.Short Interest Ratio / Days to CoverEmergent BioSolutions has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Emergent BioSolutions has recently increased by 12.53%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEmergent BioSolutions does not currently pay a dividend.Dividend GrowthEmergent BioSolutions does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-1.40 Percentage of Shares Shorted17.51% of the float of Emergent BioSolutions has been sold short.Short Interest Ratio / Days to CoverEmergent BioSolutions has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Emergent BioSolutions has recently increased by 12.53%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.74 News SentimentEmergent BioSolutions has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Emergent BioSolutions this week, compared to 5 articles on an average week.Search InterestOnly 11 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat Follows6 people have added Emergent BioSolutions to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Emergent BioSolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $204,050.00 in company stock.Percentage Held by InsidersOnly 1.20% of the stock of Emergent BioSolutions is held by insiders.Percentage Held by Institutions78.40% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Emergent BioSolutions' insider trading history. Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter. Email Address EBS Stock News HeadlinesEmergent BioSolutions: I See Further Downside Ahead In This Value TrapMarch 26, 2025 | seekingalpha.comWhat is HC Wainwright's Estimate for EBS Q1 Earnings?March 25, 2025 | americanbankingnews.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…March 30, 2025 | Paradigm Press (Ad)Emergent BioSolutions (NYSE:EBS) Earns "Buy" Rating from HC WainwrightMarch 23, 2025 | americanbankingnews.comEmergent BioSolutions sells Baltimore facility to SyngeneMarch 21, 2025 | investing.comExpert Outlook: Emergent BioSolutions Through The Eyes Of 5 AnalystsMarch 21, 2025 | benzinga.comEmergent Biosolutions’ Strategic Investments and Divestitures Justify Buy RatingMarch 21, 2025 | tipranks.comEmergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08March 20, 2025 | globenewswire.comSee More Headlines EBS Stock Analysis - Frequently Asked Questions How have EBS shares performed this year? Emergent BioSolutions' stock was trading at $9.56 at the start of the year. Since then, EBS stock has decreased by 51.1% and is now trading at $4.6750. View the best growth stocks for 2025 here. How were Emergent BioSolutions' earnings last quarter? Emergent BioSolutions Inc. (NYSE:EBS) released its quarterly earnings data on Monday, March, 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.40. The biopharmaceutical company earned $194.70 million during the quarter, compared to the consensus estimate of $254.67 million. Emergent BioSolutions had a negative trailing twelve-month return on equity of 9.91% and a negative net margin of 18.55%. Who are Emergent BioSolutions' major shareholders? Top institutional investors of Emergent BioSolutions include Vanguard Group Inc. (5.91%), American Century Companies Inc. (3.95%), Invesco Ltd. (2.84%) and Millennium Management LLC (2.74%). Insiders that own company stock include Neal Franklin Fowler, Kathryn C Zoon and Ronald Richard. View institutional ownership trends. How do I buy shares of Emergent BioSolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emergent BioSolutions own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent BioSolutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA) and Moderna (MRNA). Company Calendar Last Earnings3/03/2025Today3/30/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNYSE:EBS CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees2,420Year FoundedN/APrice Target and Rating Average Stock Price Target$14.33 High Stock Price Target$16.00 Low Stock Price Target$12.00 Potential Upside/Downside+206.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-760,500,000.00 Net Margins-18.55% Pretax Margin-15.09% Return on Equity-9.91% Return on Assets-3.31% Debt Debt-to-Equity Ratio1.30 Current Ratio2.88 Quick Ratio1.47 Sales & Book Value Annual Sales$1.01 billion Price / Sales0.25 Cash Flow$0.52 per share Price / Cash Flow8.92 Book Value$12.51 per share Price / Book0.37Miscellaneous Outstanding Shares54,337,000Free Float53,534,000Market Cap$254.03 million OptionableOptionable Beta1.80 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NYSE:EBS) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent BioSolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.